259 related articles for article (PubMed ID: 25784655)
1. Stage-specific prognostic biomarkers in melanoma.
Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
[TBL] [Abstract][Full Text] [Related]
2. Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis.
Zhang G; Cheng Y; Chen G; Tang Y; Ardekani G; Rotte A; Martinka M; McElwee K; Xu X; Wang Q; Zhou Y
Oncotarget; 2015 Sep; 6(26):23026-35. PubMed ID: 26246476
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
Lu J; Zhang G; Cheng Y; Tang Y; Dong Z; McElwee KJ; Li G
Oncol Rep; 2014 Dec; 32(6):2571-9. PubMed ID: 25310020
[TBL] [Abstract][Full Text] [Related]
5. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
7. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
[TBL] [Abstract][Full Text] [Related]
8. Melastatin expression and prognosis in cutaneous malignant melanoma.
Duncan LM; Deeds J; Cronin FE; Donovan M; Sober AJ; Kauffman M; McCarthy JJ
J Clin Oncol; 2001 Jan; 19(2):568-76. PubMed ID: 11208852
[TBL] [Abstract][Full Text] [Related]
9. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
10. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma.
Bagger M; Andersen MT; Andersen KK; Heegaard S; Andersen MK; Kiilgaard JF
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):438-44. PubMed ID: 25537201
[TBL] [Abstract][Full Text] [Related]
12. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.
Jovanovic B; Kröckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
J Invest Dermatol; 2008 Nov; 128(11):2696-2704. PubMed ID: 18509361
[TBL] [Abstract][Full Text] [Related]
13. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
[TBL] [Abstract][Full Text] [Related]
14. Metallothionein-overexpression as a prognostic marker in melanoma.
Weinlich G
G Ital Dermatol Venereol; 2009 Feb; 144(1):27-38. PubMed ID: 19218909
[TBL] [Abstract][Full Text] [Related]
15. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model.
Callender GG; Gershenwald JE; Egger ME; Scoggins CR; Martin RC; Schacherer CW; Edwards MJ; Urist MM; Ross MI; Stromberg AJ; McMasters KM
J Am Coll Surg; 2012 Apr; 214(4):608-17; discussion 617-9. PubMed ID: 22342785
[TBL] [Abstract][Full Text] [Related]
16. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability.
Hahn S; Ugurel S; Hanschmann KM; Strobel H; Tondera C; Schadendorf D; Löwer J; Löwer R
AIDS Res Hum Retroviruses; 2008 May; 24(5):717-23. PubMed ID: 18462078
[TBL] [Abstract][Full Text] [Related]
17. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
[TBL] [Abstract][Full Text] [Related]
18. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
19. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
